Syndax Pharmaceuticals (FRA:1T3) ROC %: -340.11% (As of Mar. 2026)

What is Syndax Pharmaceuticals ROC %?

Syndax Pharmaceuticals FRA:1T3 -0.94% 25 ROC % is -340.11% as of Mar. 2026. GuruFocus rates FRA:1T3 with a GF Score™ of 25/100. The stock has 7 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Syndax Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -340.11%.

As of today (2026-06-28), Syndax Pharmaceuticals's WACC % is 8.93%. Syndax Pharmaceuticals's ROC % is -300.30% (calculated using TTM income statement data). Syndax Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Syndax Pharmaceuticals (FRA:1T3) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Syndax Pharmaceuticals's WACC % is 8.93%. Syndax Pharmaceuticals's ROC % is -300.30% (calculated using TTM income statement data). Syndax Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Syndax Pharmaceuticals ROC % Related Terms

Syndax Pharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals ROC % Chart

Syndax Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

312.59

-1,392.35

-766.85

-351.23

-266.64

Syndax Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROC %	Get a 7-Day Free Trial															-245.04	-240.20	-263.08	-476.47	-340.11

25GF Score

Syndax Pharmaceuticals Inc FRA:1T3

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Syndax Pharmaceuticals ROC % Calculation

Syndax Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-233.214 * ( 1 - 0% )	/	( (143.347	+	31.581)	/ 2 )
=	-233.214	/	87.464
=	-266.64 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	692.199	-	71.822	-	( 556.682	-	max(0, 98.889	-	575.919	+	556.682	))
=	143.347

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	452.369	-	72.386	-	( 353.288	-	max(0, 102.579	-	450.981	+	353.288	))
=	31.581

Syndax Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-118.34 * ( 1 - 0% )	/	( (31.581	+	38.009)	/ 2 )
=	-118.34	/	34.795
=	-340.11 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	452.369	-	72.386	-	( 353.288	-	max(0, 102.579	-	450.981	+	353.288	))
=	31.581

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	408.858	-	58.377	-	( 312.472	-	max(0, 74.541	-	407.568	+	312.472	))
=	38.009

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -340.11% mean?

Syndax Pharmaceuticals (FRA:1T3) has a ROC % of -340.11% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Syndax Pharmaceuticals and its competitors.

Is Syndax Pharmaceuticals' ROC % too high?

Syndax Pharmaceuticals' current ROC % is -340.11%. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.

How does Syndax Pharmaceuticals' ROC % compare to CAPR and SLS?

Syndax Pharmaceuticals' ROC % of -340.11% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current ROC % is -340.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Syndax Pharmaceuticals stock overvalued right now?

Syndax Pharmaceuticals (FRA:1T3) has a current ROC % of -340.11%. The current ROC % is -340.11%. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current ROC % is -340.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies CAPR SLS AGIO VCEL PVLA TSHA GENB QURE ATAI NVAX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges SNDX:USA 1T3:Germany

Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017

Website https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

25GF Score

Get the complete analysis for FRA:1T3

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.43

Price

View FRA:1T3 Analysis

See ROC % data for all stocks →